Mesothelioma
Conditions
Brief summary
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
Detailed description
This is a multicentric cross-sectional observational study with an additional blood volume collected during blood sampling performed for normal clinical practice. The enrollment will take
Interventions
None listed
Sponsors
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Marco Emilio Bianchi
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with Mesothelioma: Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma. * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women. * Capacity to comprehend the study nature and provide autonomously informed consent. Control Group patients: * Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious). * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women. * Ability to understand the study nature and provide autonomously informed consent. If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study.
Exclusion criteria
* Lack of biopsy material. * pregnancy. * Unwillingness to sign the Informed Consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To set up spheroids models to study and serve as a platform | 0/baseline | Number of spheroids with infiltrated macrophages. About of 30% of macrophages infiltrated into spheroids. |
| To set up spheroids models and serve as a platform | 0/baseline | Evaluation of macrophages polarization status M1 or M2 based on different genes and proteins expression using qPCR and Flow Cytometry. |
| To set up organoid models | 0/baseline | Number of organoids formation. About of 30% of biopsies generated organoids. |
| Test inhibitors on spheroids and organoids and assess the response of individual patients to therapy | 0/baseline | Rate of growth to test the efficacy of anti-CSF1R, BoxA and DFL using human mesospheres from MPM primary cell lines derived from patients and monocytes from controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To investigate inhibitors of the CXCR4-CXCL12-HMGB1 axis on the crosstalk | 0/baseline | Percentage of migrated or invaded MPM cell lines NCI-H2052 (BAP1 WT/NF2 MUT) vs NCI-H28 (BAP1 mut/NF2 WT) with and without macrophages in presence of CDDP-Nivolumab (NIVO)-Peptide R54. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Repurposing Diflunisal as antitumor drug in MPM | In vivo experiment 3 weeks. | Overall survival of MPM mice treated with DFL in combination with the gold-standard treatment of MM patients, i.e. checkpoint inhibitors (Nivolumab + Ipilimumab). |
Countries
Italy
Contacts
Primary ContactMassimo Crippa, PhD
Outcome results
None listed